> ## Content Index
> Fetch the complete content index at: https://bioweek.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Roche Bets $2.3 Billion on Muscle-Preserving Obesity Biology
- URL: https://bioweek.com/roche-bets-2-3-billion-on-muscle-preserving-obesity-biology/
- Published: 2026-08-30T10:43:35.000Z
- Updated: 2026-08-30T17:00:28.000Z
- Description: Roche subsidiary Genentech is paying Hanmi Pharmaceutical $190 million upfront for a non-incretin urocortin-2 analog designed to burn fat while sparing lean muscle mass.
- Author: BioWeek
- Tags: Pipeline, Markets

The first generation of incretin blockbusters proved that pharmaceutical appetite suppression can strip 15% to 25% of a patient's body weight. The clinical catch has been what vanishes alongside the adipose tissue: up to 40% of the total mass lost on GLP-1 receptor agonists can come directly from skeletal muscle, raising metabolic and physical frailty risks for long-term patients.

Roche subsidiary Genentech is committing up to $2.3 billion to commercialize an entirely different biological mechanism aimed squarely at that limitation. Under an exclusive global licensing [agreement](https://www.bioxconomy.com/partnering/hanmi-inks-2-3bn-deal-with-genentech-for-obesity-therapy?ref=bioweek.com), Genentech will pay South Korea's Hanmi Pharmaceutical $190 million in upfront cash, with development, regulatory, and sales milestones pushing the total potential value past $2.3 billion, alongside tiered royalties.

The asset, designated HM17321, is a long-acting analog of urocortin-2 (UCN2) that acts selectively on corticotropin-releasing factor receptor 2 (CRFR2). While dominant incretin therapies target hypothalamic feeding circuits in the brain and gut motility, CRFR2 signaling works primarily in peripheral tissues to modulate glucose uptake, stimulate skeletal muscle hypertrophy, and accelerate fatty acid oxidation.

### Beyond the Brain-Gut Axis

Hanmi cleared an Investigational New Drug application with the U.S. Food and Drug Administration in November 2025 and is currently conducting a Phase 1 clinical trial assessing the safety, tolerability, and pharmacokinetics of HM17321 in healthy volunteers and patients with obesity. Under the deal structure, Hanmi will complete the Phase 1 program before handing worldwide clinical development and commercialization to Genentech, while retaining exclusive rights in South Korea.

Preclinical data presented at medical [meetings](https://doi.org/10.2337/db25-886-p?ref=bioweek.com) showed that HM17321 monotherapy stimulated lean muscle growth while selectively reducing adipose tissue in diet-induced obese mice. When researchers combined the peptide with incretin agonists, the regimen deepened total fat reduction while preventing the loss of skeletal muscle mass and functional grip strength.

For Genentech and parent company Roche, the transaction represents an aggressive expansion into second-generation cardiometabolic medicine. Following its $2.7 billion acquisition of Carmot Therapeutics in late 2023, Roche built an incretin pipeline featuring dual GLP-1/GIP agonists CT-388 and CT-996\. Adding a peripheral, non-incretin peptide provides a biological counterweight that Roche can evaluate as a standalone therapy or combine directly with incretin backbones.

### The Shift to Body Composition Quality

The deal reflects a broader maturation across the metabolic disease landscape. Where early drug development prioritized gross weight reduction on the scale, biopharma developers and clinicians increasingly evaluate body composition quality, including the ratio of visceral fat loss to lean muscle preservation.

Competitors are exploring several biological angles to protect muscle, including myostatin and activin receptor antagonists such as bimagrumab and apitegromab. HM17321 offers a distinct approach through direct CRFR2 agonism, avoiding antibody-mediated pathway blockade in favor of a peptide designed to enhance cellular energy metabolism directly in muscle tissue.

If Phase 1 trials confirm human safety and pharmacodynamic activity, Genentech plans to advance HM17321 into Phase 2 clinical studies exploring both monotherapy in obesity and combination regimens with incretin backbones, testing whether preserving muscle mass can translate into durable, higher-quality weight management.